search button

A clinical study of cytokine-induced killer cells for the treatment of refractory lymphoma

  • Authors:
    • Zhi Guo
    • Hao Liu
    • Xue-Peng He
    • Xiao-Hua Tan
    • Yan Zhou
    • Xia Chen
    • Yu-Jie Shi
    • Xiao-Dong Liu
    • Hui-Ren Chen

  • View Affiliations

  • Published online on: March 15, 2011     https://doi.org/10.3892/ol.2011.269
  • Pages: 531-536
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cytokine-induced killer (CIK) cell therapy, an adoptive T-cell immunotherapy, has been reported to be a safe and effective mode of treatment for patients with metastatic diseases, lymphoma and acute leukaemia. To investigate the clinical efficacy of cytokine-induced killer cells for the treatment of refractory lymphoma, the present clinical study was conducted. A total of 8 male patients with a mean age of 41 years (range 22-65) who were pathologically diagnosed with malignant lymphoma (Hodgkin's disease, 2 and non-Hodgkin's lymphoma, 6) were enrolled. CIK cells were expanded by priming with IFN-γ, monoclonal antibody (mAb) to CD3 and IL-1α, followed by the addition of IL-2 the following day using peripheral blood mononuclear cells (PBMCs) of the 8 male patients. The CIK cells were then transfused back to the patients as treatment. On day 13, the CIK cell count reached 7-18x1019 (mean, 12.7x109), a 44- to 140-fold increase (mean, 98-fold). The average percentage of cells expressing CD3+, CD4+, CD8+ and CD3+CD56+ were also increased from 50.9±3.5, 29.9±1.7, 41.3±3.2, 1.6±0.2% to 90.2±1.6, 40.6±5.5, 52.8±4.9 and 33.1±4.0%, respectively. Patients showed measurable radiographic tumor reduction, increased T-cell subset levels, and relief of symptoms after treatment. No severe toxicity or side effects were reported. CIK cells developed by this culture method have a high in vitro proliferation rate and tumor-killing capacity. In conclusion, CIK cell treatment of patients with malignant lymphoma achieves effective clinical responses, causing few side effects.
View Figures
View References

Related Articles

Journal Cover

May-June 2011
Volume 2 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Guo Z, Liu H, He X, Tan X, Zhou Y, Chen X, Shi Y, Liu X and Chen H: A clinical study of cytokine-induced killer cells for the treatment of refractory lymphoma. Oncol Lett 2: 531-536, 2011
APA
Guo, Z., Liu, H., He, X., Tan, X., Zhou, Y., Chen, X. ... Chen, H. (2011). A clinical study of cytokine-induced killer cells for the treatment of refractory lymphoma. Oncology Letters, 2, 531-536. https://doi.org/10.3892/ol.2011.269
MLA
Guo, Z., Liu, H., He, X., Tan, X., Zhou, Y., Chen, X., Shi, Y., Liu, X., Chen, H."A clinical study of cytokine-induced killer cells for the treatment of refractory lymphoma". Oncology Letters 2.3 (2011): 531-536.
Chicago
Guo, Z., Liu, H., He, X., Tan, X., Zhou, Y., Chen, X., Shi, Y., Liu, X., Chen, H."A clinical study of cytokine-induced killer cells for the treatment of refractory lymphoma". Oncology Letters 2, no. 3 (2011): 531-536. https://doi.org/10.3892/ol.2011.269